169 related articles for article (PubMed ID: 33489928)
1. A Novel Triple-Fluorescent HCMV Strain Reveals Gene Expression Dynamics and Anti-Herpesviral Drug Mechanisms.
Rand U; Kubsch T; Kasmapour B; Cicin-Sain L
Front Cell Infect Microbiol; 2020; 10():536150. PubMed ID: 33489928
[TBL] [Abstract][Full Text] [Related]
2. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.
Wildum S; Zimmermann H; Lischka P
Antimicrob Agents Chemother; 2015; 59(6):3140-8. PubMed ID: 25779572
[TBL] [Abstract][Full Text] [Related]
3. Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity.
Hahn F; Hutterer C; Henry C; Hamilton ST; Strojan H; Kraut A; Schulte U; Schütz M; Kohrt S; Wangen C; Pfizer J; Couté Y; Rawlinson WD; Strobl S; Marschall M
Antiviral Res; 2018 Nov; 159():84-94. PubMed ID: 30268914
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) exert a strong anti-herpesviral activity.
Hutterer C; Milbradt J; Hamilton S; Zaja M; Leban J; Henry C; Vitt D; Steingruber M; Sonntag E; Zeitträger I; Bahsi H; Stamminger T; Rawlinson W; Strobl S; Marschall M
Antiviral Res; 2017 Jul; 143():113-121. PubMed ID: 28400201
[TBL] [Abstract][Full Text] [Related]
5. Thioxothiazolo[3,4-a]quinazoline derivatives inhibit the human cytomegalovirus alkaline nuclease.
Zhang T; Potgieter TI; Kosche E; Rückert J; Ostermann E; Schulz T; Empting M; Brune W
Antiviral Res; 2023 Sep; 217():105696. PubMed ID: 37541625
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic significance and clinical impact of quantitative assays for diagnosis of human cytomegalovirus infection/disease in immunocompromised patients.
Gerna G; Percivalle E; Baldanti F; Sarasini A; Zavattoni M; Furione M; Torsellini M; Revello MG
New Microbiol; 1998 Jul; 21(3):293-308. PubMed ID: 9699213
[TBL] [Abstract][Full Text] [Related]
7.
Ghassabian H; Falchi F; Timmoneri M; Mercorelli B; Loregian A; Palù G; Alvisi G
Viruses; 2021 May; 13(5):. PubMed ID: 34065234
[TBL] [Abstract][Full Text] [Related]
8. Investigational Antiviral Therapy Models for the Prevention and Treatment of Congenital Cytomegalovirus Infection during Pregnancy.
Hamilton ST; Marschall M; Rawlinson WD
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077661
[TBL] [Abstract][Full Text] [Related]
9. Drug targets in cytomegalovirus infection.
Andrei G; De Clercq E; Snoeck R
Infect Disord Drug Targets; 2009 Apr; 9(2):201-22. PubMed ID: 19275707
[TBL] [Abstract][Full Text] [Related]
10. The c-Jun N-terminal kinase inhibitor SP600125 inhibits human cytomegalovirus replication.
Zhang H; Niu X; Qian Z; Qian J; Xuan B
J Med Virol; 2015 Dec; 87(12):2135-44. PubMed ID: 26058558
[TBL] [Abstract][Full Text] [Related]
11. The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease.
Hussein ITM; Brooks J; Bowlin TL
Antiviral Res; 2020 Apr; 176():104710. PubMed ID: 31940473
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
13. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.
Gilbert C; Boivin G
Antimicrob Agents Chemother; 2005 Dec; 49(12):4860-6. PubMed ID: 16304146
[TBL] [Abstract][Full Text] [Related]
14. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood.
Baldanti F; Simoncini L; Sarasini A; Zavattoni M; Grossi P; Revello MG; Gerna G
Transplantation; 1998 Aug; 66(3):324-9. PubMed ID: 9721800
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological and clinical effects of letermovir (Prevymis
Ogawa M; Eto T
Nihon Yakurigaku Zasshi; 2019; 153(4):192-198. PubMed ID: 30971660
[TBL] [Abstract][Full Text] [Related]
16. An overview of letermovir: a cytomegalovirus prophylactic option.
Gerna G; Lilleri D; Baldanti F
Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
[No Abstract] [Full Text] [Related]
17. A Luciferase Gene Driven by an Alphaherpesviral Promoter Also Responds to Immediate Early Antigens of the Betaherpesvirus HCMV, Allowing Comparative Analyses of Different Human Herpesviruses in One Reporter Cell Line.
Maier AK; Jung R; Villinger C; Schubert A; Walther P; Sinzger C; Lieber D
PLoS One; 2017; 12(1):e0169580. PubMed ID: 28060895
[TBL] [Abstract][Full Text] [Related]
18. Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients.
Sarasini A; Baldanti F; Furione M; Percivalle E; Brerra R; Barbi M; Gerna G
J Med Virol; 1995 Nov; 47(3):237-44. PubMed ID: 8551275
[TBL] [Abstract][Full Text] [Related]
19. Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein.
Mercorelli B; Luganini A; Celegato M; Palù G; Gribaudo G; Loregian A
Antiviral Res; 2018 Feb; 150():130-136. PubMed ID: 29274844
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
